Brevibacterium casei endophthalmitis after intravitreal dexamethasone implant
| Autor: | Antonio Duch-Samper, D. Hernández-Pérez, N. Ruíz-del-Río, R.A. Díaz-Céspedes, Á. Olate-Pérez |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pars plana
medicine.medical_specialty biology business.industry medicine.drug_class medicine.medical_treatment Antibiotics Brevibacterium Vitrectomy General Medicine medicine.disease biology.organism_classification medicine.anatomical_structure Endophthalmitis Ophthalmology Medicine Implant Brevibacterium casei business Dexamethasone medicine.drug |
| Zdroj: | Archivos de la Sociedad Espanola de Oftalmologia r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA instname |
| ISSN: | 2173-5794 1989-7286 |
| DOI: | 10.1016/j.oftale.2020.09.010 |
| Popis: | CLINICAL CASE: A 49-year-old man with diabetic macular edema refractory to antiangiogenics was treated with intravitreal dexamethasone implant (Ozurdex; Allergan, California, USA). Seven days after treatment, he showed acute endophthalmitis suggestive signs. Despite the intravitreal injection of antibiotics, the patient got worse. Vitreous sampling was repeated for Gram and cultures, and vitrectomy was performed via pars plana. The culture suggested the development of Brevibacterium species. Through an additional test, the presence of Brevibacterium casei was confirmed. Despite the treatment adjusted by antibiogram, retinal ischemia and macular atrophy was evident. DISCUSION: Brevibacterium casei is a Gram-positive bacterium, barely pathogenic, that mainly affects immunodepressed patients. Only two cases of endophthalmitis are described, one endogenous and the other one secondary to vegetal trauma. This is the first case of Brevibacterium casei endophthalmitis, secondary to an ophthalmological procedure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect